Eagle Pharmaceuticals, Inc. announced the availability of their unaudited financial statements for the first quarter of 2025. The company is focused on developing innovative medicines to improve patients’ lives, with a portfolio of commercialized products and a pipeline of oncology and CNS/metabolic critical care candidates. For more information, visit their website at www.eagleus.com. Investor relations can be contacted through Lisa M. Wilson at [email protected] or 212-452-2793.

Read more at GlobeNewswire: Eagle Pharmaceuticals Announces Availability of Unaudited